BRISBANE, Australia, Dec. 3, 2019 /PRNewswire/ — QBiotics Group Limited (QGL), a life sciences company developing novel anticancer and wound healing pharmaceuticals, today announced that it has dosed its first patient in a Phase I/II clinical trial evaluating...
Companies to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer Seattle Genetics, Inc. and Astellas Pharma Inc.have announced a clinical collaboration agreement with Merck, known as MSD outside the...
No evidence of cardiotoxicity to date; 40% of 10 patients dosed at ≥120 mg/m² demonstrate efficacy; trial progresses in Europe to 210 mg/m² HOUSTON, Dec. 4, 2019 /PRNewswire/ — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the...
Baseline-matched Real-World external Control Data with Alzheimer’s Disease Neuroimaging Initiative (ADNI): ANAVEX®2-73 (blarcamesine) Cohort showed a Significantly lower Cognitive Decline Compared to the ADNI Control Cohort at Interim 2-Year (104-Week) Timepoint...
ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced the recent achievement of two significant clinical trial milestones, enrollment of 60...
First patient successfully dosed in QBiotics’ Phase I/II clinical trial of tigilanol tiglate in patients with Head and Neck Squamous Cell Carcinoma (HNSCC) Tigilanol tiglate is a novel, small molecule that is being tested as a single injection treatment for...
Email
Text